Search research articles
Contact Us
Filters
Showing results (321-330 of 397) with videos related to
Page
of 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
Cancer
|
December 9, 2022
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer
Diego de Miguel-Perez, Alessandro Russo, Muthukumar Gunasekaran, et al.
Oncotarget
|
November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
Mehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Journal of Gynecologic Oncology
|
April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Young Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Page
of 40
Search research articles
Search
Showing results (321-330 of 397) with videos related to
Sort By:
Page
of 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
Cancer
|
December 9, 2022
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer
Diego de Miguel-Perez, Alessandro Russo, Muthukumar Gunasekaran, et al.
Oncotarget
|
November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
Mehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Journal of Gynecologic Oncology
|
April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Young Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Page
of 40